Multiparametric Imaging in Multiple Myeloma

Yingbing Wang10 enrolled

Overview

Patients with Multiple Myeloma will undergo single timepoint Positron Emission Tomography imaging with intravenously injected C11 Methionine to detect viable lesions.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Multiple Myeloma

Interventions

C11 Methionine positron emission tomographyDRUG

diagnostic positron emission tomography imaging after intravenous injection of C11 Methionine

Eligibility

Sex: ALLMin age: 40 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of Multiple Myeloma with symptomatic bone or soft tissue disease * Eastern Cooperative Oncology Group status 0 to 2 * Life expectance \>= 12 weeks * Ability to understand and willingness to sign informed consent * Tissue sampling with genotype data planned within 3 months of C11 positron emission tomography (PET) imaging Exclusion Criteria: * Pregnant or breast feeding * Claustrophobic reactions and unable to lie still on a bed inside the PET scanner for 60 minutes * Research related radiation exposure exceeding 50 millisieverts

Locations (1)

Massachusetts General Hospital

Boston, Massachusetts, United States

Outcomes

Primary Outcomes

Quantitative measure of C11 Methionine uptake

Standardized uptake value (a semiquantitative, unit less measure of radioactivity normalized for injected activity and body weight) will be measured for individual C11 Methionine uptake abnormalities (defined as focally increased uptake higher than background levels in a similar tissue type). All abnormal uptake not in locations common for benign etiologies, such as fracture and degenerative change, will be measured.

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.